Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

Somehow, it’s becoming even harder to get a GLP-1.

Leaving the Obamacare exchange, closing some Oak Street clinics and taking a $5.7 billion charge have CVS Health on a better financial path.

Eli Lilly's Q3 results hinge on strong demand for Mounjaro and Zepbound as investors weigh growth drivers against the ...

October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...

Mounjaro generated sales of $6.5bn in Q3 2025, up 109% from the same period in 2024. Zepbound exhibited even higher growth – ...

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication more accessible nationwide.

Yhe change will reduce their monthly cost for a brand-name prescription by an average of 30%, according to the company.

Walmart is joining Costco, Sam’s Club, and CVS in offering cheaper prices for customers paying out of pocket for Zepbound, ...

CVS Caremark, the largest PBM in the U.S., tells activists Gilead needs to lower the price of its new HIV drug to get on ...

Philadelphia has sued major pharmacy benefit managers, alleging their marketing and distribution of opioids contributed to ...

Explore how GLP-1 drugs like Ozempic, Wegovy, and Mounjaro are impacting obesity rates in America, while also highlighting ...